Zydus enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated July 07, 2016 titled "Zydus enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir". AGM on August 03, 2016
Cadila Healthcare Ltd has informed BSE that the 21st Annual General Meeting (AGM) of the Company will be held on August 03, 2016. Updates
Cadila Healthcare Ltd has informed BSE that the Company's Moraiya manufacturing facility has received an Establishment Inspection Report (EIR) from the USFDA. This receipt of EIR only indicates closure of the inspection points (483s) raised based on the inspection carried out between August 28, 2014 and September 05, 2014. What is "closed" is the initial review that resulted in the warning letter issuance. Though this is a positive step towards the... Buy Cadila Healthcare Ltd., target Rs 355 : Gaurav Bissa
Buy Cadila Healthcare Ltd. at a price target of Rs 355 and a stop loss at Rs 337 Audit Report - in respect of Sharepro Services (India) Private Limited (Sharepro)
Cadila Healthcare Ltd has informed BSE regarding "Audit Report - in respect of Sharepro Services (India) Private Limited (Sharepro)". Zydus acquires two ANDAs from Teva, strengthens its US portfolio
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 20, 2016 titled "Zydus acquires two ANDAs from Teva, strengthens its US portfolio". Zydus Cadila inks pact with Turkish firm
Healthcare provider Zydus Cadila, on Wednesday, announced the signing of a collaboration agreement with Turkey's Eczacibasi Ilac Pazarlama, A.S., to market biotech products in the Turkish market. T... Zydus Cadila and Eczacibasi, a Turkish Healthcare Company, enter into a strategic collaboration to market biosimilars in Turkey
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 15, 2016, titled "Zydus Cadila and Eczacibasi, a Turkish Healthcare Company, enter into a strategic collaboration to market biosimilars in Turkey". Buy Cadila Healthcare, target Rs 335-340: Siddarth Bhamre
The stock has fallen 3.6 per cent so far this calendar. It is trading at a P/E of 21.45. The stock is making an attempt to move above its 20-, 50- and 100-day moving averages New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 11, 2016, titled "New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions."